Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned an average recommendation of “Buy” from the ten research firms that are covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $9.31.

A number of equities research analysts have recently weighed in on TRVI shares. HC Wainwright lifted their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th. B. Riley reaffirmed a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research report on Monday, October 7th. D. Boral Capital reissued a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Thursday, December 12th.

Trevi Therapeutics Trading Down 1.0 %

Shares of TRVI opened at $4.03 on Thursday. The company’s 50-day moving average price is $3.37 and its 200 day moving average price is $3.13. Trevi Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.68. The firm has a market cap of $309.77 million, a P/E ratio of -9.16 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the firm earned ($0.08) EPS. Equities research analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TRVI. JPMorgan Chase & Co. lifted its holdings in Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after buying an additional 69,167 shares during the last quarter. Barclays PLC lifted its stake in Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares in the last quarter. State Street Corp increased its stake in Trevi Therapeutics by 5.9% in the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after purchasing an additional 53,051 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new stake in Trevi Therapeutics during the third quarter worth approximately $256,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.